- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04898972
Mindfulness-based Intervention in COPD Dyads (MIND)
August 2, 2021 updated by: Maria Matarese, Campus Bio-Medico University
Mindfulness-based Stress Reduction Intervention in Patients With COPD and Their Caregivers
This study evaluates the effectiveness of a Mindfulness-Based Stress Reduction intervention (MBSRI) on the reduction of stress, anxiety, and depression in people with COPD and their family caregivers.
The experimental group will receive the MBSRI and the control group an informational intervention on stress management.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
People affected by Chronic Obstructive Pulmonary Disease (COPD) and their family caregivers (named dyads) often suffer from psychological distress, because of the physical problems and social isolation imposed by the disease.
Such psychological distress can influence the ability of patients and caregivers to manage the disease.
Mindfulness-based interventions have showed benefits in improving the psychological status in various clinical situations.
A 8-week mindfulness based-stress reduction intervention will be offered to a group of COPD patient-caregiver dyads and its effectiveness will be assessed comparing the effects on a control group to whom an informational intervention on stress reduction will be carried out.
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Maria Matarese
- Phone Number: 1026 003922541
- Email: m.matarese@unicampus.it
Study Contact Backup
- Name: Claudio Pedone
- Phone Number: 1336 00392251
- Email: c.pedone@unicampus.it
Study Locations
-
-
-
Rome, Italy, 00121
- Recruiting
- Campus Bio-Medico University of Rome
-
Contact:
- Maria Matarese
- Phone Number: 003906225411026
- Email: m.matarese@unicampus.it
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Persons able to read and understand Italian.
- people affected by COPD stage C (GOLD 3 o 4, and/or 2 or more exacerbations per year or 1 or more hospitalizations for exacerbations and score of COPD assessment test-CAT < 10 or mMRC 0-1).
- People affected by COPD stage D (GOLD 3 o 4, and/or 2 or more exacerbations per year or 1 or more hospitalizations for exacerbations and score of COPD assessment test-CAT ≥ 10 or mMRC ≥ 2).
Exclusion Criteria:
- Persons or dyads not able to guarantee the presence on the MBSR intervention sessions for the four months requested.
- Persons with diagnosis of anxiety or depression.
- Persons that have practiced before or actually practice yoga or mindfulness.
- Persons with cognitive impairment.
- Persons under continuous oxygen therapy.
- Persons with diagnosis of cancer or other terminal diseases or any psychiatric problem.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Mindfulness-based stress reduction intervention
Patient-family caregiver dyads will take part in 8-week Mindfulness-based stress reduction intervention (MBSR).
|
The 8-group sessions of MBSR will be conducted once a week, lasting two and a half hours, with two additional sessions in the following two months.
Between sessions, participants will have to practice at home for 45 minutes a day, 6 days a week.
For the practice, patients and caregivers will be provided with audio files containing the meditations proposed in the classroom, readings, and the diary of the practice.
During the sessions, the following mindfulness-based techniques will be introduced: body scan; sitting meditation; awareness movement exercises; and walking meditation.The sessions will be held face to face or online using common videoconferencing platforms, such as Skype or Zoom, based on the preferences of the participants.
This will facilitate the participation of patients and caregivers, overcoming the obstacles related to travel.
The course will be taught by certified mindfulness teachers with experience in MBSR interventions on patients with respiratory diseases.
|
|
Active Comparator: information booklet
Patient-informal caregiver dyads will receive an informative booklet on stress reduction strategies
|
COPD patient-caregiver dyads will be delivered by hand, sent by email or by post an information booklet "Coping with your chronic disease", targeting COPD patients, to teach them how to manage stress.
This booklet, available in Italian, provides simple information on the meaning of stress and anxiety, and suggests some actions that people can implement at home to reduce stress.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in perceived stress measured by Perceived Stress Scale (PSS) at 8 weeks and 16 weeks
Time Frame: at baseline, after 8 weeks, and after 16 weeks from baseline
|
The perceived stress entails the feelings or thoughts that an individual has about how much stress they are under at a given point in time.
It will be measured in patients and caregivers using the Perceived Stress Scale (PSS) that is a 10 item-self-report instrument: its score ranges from 0 to to 40 with higher scores indicating higher perceived stress.
Scores ranging from 0-13 would be considered low stress.
Change = (8 weeks- baseline scores) (16 weeks-baseline scores), and (16-weeks-8 weeks scores).
|
at baseline, after 8 weeks, and after 16 weeks from baseline
|
|
Change from baseline in anxiety level measured by Generalized Anxiety Disorder scale (GAD-7) at 8 weeks and 16 weeks.
Time Frame: at baseline, after 8 weeks, and after 16 weeks from baseline
|
The anxiety level will be measured in patients and caregivers using the 7-item Generalized Anxiety Disorder scale (GAD-7).
Its scores range from 0 to 21. Cut points of 5, 10, and 15 represent mild, moderate, and severe levels of anxiety.
Change = (8 weeks- baseline scores) (16 weeks-baseline scores), and (16-weeks-8 weeks scores).
|
at baseline, after 8 weeks, and after 16 weeks from baseline
|
|
Change from baseline in depression measured by Patient Health Questionnaire (PHQ-9) at 8 weeks and 16 weeks
Time Frame: at baseline, after 8 weeks, and after 16 weeks from baseline
|
The depressive symptoms in patients and caregivers will be measured using the 9-item Patient Health Questionnaire (PHQ-9).
Its score range from 0 (no symptoms) to 27 (nearly daily symptoms).
Scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe and severe depression, respectively.
Change = (8 weeks- baseline scores) (16 weeks-baseline scores), and (16-weeks-8 weeks scores).
|
at baseline, after 8 weeks, and after 16 weeks from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in subjective quality of sleep measured by the Pittsburgh Sleep Quality Index (PSQI) at 8 and 16 weeks.
Time Frame: at baseline, after 8 weeks, and after 16 weeks from baseline
|
The quality and patterns of sleep in patients and caregivers will be measured by PSQI that is a self-report questionnaire measuring seven areas: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction.
The global score ranges from 0 to 21, the higher the score, the worse the sleep quality.
A global score of 5 or more indicates poor sleep quality; Change = (8 weeks- baseline scores) (16 weeks-baseline scores), and (16-weeks-8 weeks scores).
|
at baseline, after 8 weeks, and after 16 weeks from baseline
|
|
Change from baseline in mindfulness experience measured by Five Facet Mindfulness Questionnaire (FFMQ) at 8 and 16 weeks.
Time Frame: at baseline, after 8 weeks, and after 16 weeks from baseline
|
The mindfulness abilities in patients and caregivers will be measured by a self-reported questionnaire, FFMQ, that comprises 39 items assessing five facets of mindfulness: observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience.
Higher global score shows a higher mindfulness disposition.
Change = (8 weeks- baseline score), (16 weeks-baseline scores), and (16 weeks-8 weeks scores).
|
at baseline, after 8 weeks, and after 16 weeks from baseline
|
|
Change in health-related quality of life measured by Short Form 12 Health Survey (SF-12) at 8 and 16 weeks
Time Frame: at baseline, after 8 weeks, and after 16 weeks from baseline
|
The physical and mental health-related quality of life of patients and caregivers will by measured by the SF-12 that comprises 12 items.
Higher the scores the better the quality of life.
Change = (8 weeks- baseline scores), (16 weeks-baseline scores), and (16 weeks-8 weeks scores).
|
at baseline, after 8 weeks, and after 16 weeks from baseline
|
|
Change in impact of the COPD on patient's life measured by COPD Assessment Test (CAT) at 8 weeks and 16 weeks
Time Frame: at baseline, after 8 weeks, and after 16 weeks from baseline
|
The CAT is a 8-item instrument that assesses health-related quality of life and symptom burden in COPD patients.
Range of CAT scores from 0-40.
Higher scores denote a more severe impact.
Change = (8 weeks- baseline scores), (16 weeks-baseline scores), and (16 weeks-8 weeks scores).
|
at baseline, after 8 weeks, and after 16 weeks from baseline
|
|
Change in patient's dyspnea measured by the Modified Medical Research Council scale (mMRC) at 8 and 16 weeks
Time Frame: at baseline, after 8 weeks, and after 16 weeks from baseline
|
The mMRC is a 5-point (0-4) scale that will be used to measure the severity of dyspnea in patients.
Higher scores mean worse dyspnea.
Change = (8 weeks-baseline scores), (16 weeks-baseline scores), and (16 weeks-8 weeks scores).
|
at baseline, after 8 weeks, and after 16 weeks from baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Maria Matarese, Campus Bio-Medico University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96. No abstract available.
- Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.
- Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using self-report assessment methods to explore facets of mindfulness. Assessment. 2006 Mar;13(1):27-45. doi: 10.1177/1073191105283504.
- Brown KW, Ryan RM. The benefits of being present: mindfulness and its role in psychological well-being. J Pers Soc Psychol. 2003 Apr;84(4):822-48. doi: 10.1037/0022-3514.84.4.822.
- Kabat-Zinn J. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. Gen Hosp Psychiatry. 1982 Apr;4(1):33-47. doi: 10.1016/0163-8343(82)90026-3.
- Hofmann SG, Sawyer AT, Witt AA, Oh D. The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. J Consult Clin Psychol. 2010 Apr;78(2):169-83. doi: 10.1037/a0018555.
- Chan RR, Giardino N, Larson JL. A pilot study: mindfulness meditation intervention in COPD. Int J Chron Obstruct Pulmon Dis. 2015 Mar 2;10:445-54. doi: 10.2147/COPD.S73864. eCollection 2015.
- Harrison SL, Lee A, Goldstein RS, Brooks D. Perspectives of healthcare professionals and patients on the application of mindfulness in individuals with chronic obstructive pulmonary disease. Patient Educ Couns. 2017 Feb;100(2):337-342. doi: 10.1016/j.pec.2016.08.018. Epub 2016 Aug 20.
- Harrison SL, Lee A, Janaudis-Ferreira T, Goldstein RS, Brooks D. Mindfulness in people with a respiratory diagnosis: A systematic review. Patient Educ Couns. 2016 Mar;99(3):348-355. doi: 10.1016/j.pec.2015.10.013. Epub 2015 Oct 23.
- Mularski RA, Munjas BA, Lorenz KA, Sun S, Robertson SJ, Schmelzer W, Kim AC, Shekelle PG. Randomized controlled trial of mindfulness-based therapy for dyspnea in chronic obstructive lung disease. J Altern Complement Med. 2009 Oct;15(10):1083-90. doi: 10.1089/acm.2009.0037.
- Pbert L, Madison JM, Druker S, Olendzki N, Magner R, Reed G, Allison J, Carmody J. Effect of mindfulness training on asthma quality of life and lung function: a randomised controlled trial. Thorax. 2012 Sep;67(9):769-76. doi: 10.1136/thoraxjnl-2011-200253. Epub 2012 Apr 27.
- Clari, M., Conti, A., Fontanella, R., Rossi, A., & Matarese, M. (2020). Mindfulness-based programs for people with chronic obstructive pulmonary disease: a mixed methods systematic review. Mindfulness, 1-20.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 20, 2021
Primary Completion (Anticipated)
December 30, 2023
Study Completion (Anticipated)
December 30, 2023
Study Registration Dates
First Submitted
May 19, 2021
First Submitted That Met QC Criteria
May 19, 2021
First Posted (Actual)
May 24, 2021
Study Record Updates
Last Update Posted (Actual)
August 3, 2021
Last Update Submitted That Met QC Criteria
August 2, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 29.17 OSS ComEt CBM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Individual participant data that will be used in the result publications.
IPD Sharing Time Frame
From the date of study publication up to 4 years later
IPD Sharing Access Criteria
Formal request by email from researchers affiliated to university centers
IPD Sharing Supporting Information Type
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
University of LeicesterUniversity Hospitals, Leicester; University of StrathclydeRecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway DiseaseUnited Kingdom
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Mindfulness-based stress reduction intervention
-
Fatima Jinnah Women UniversityCompleted
-
İstanbul Yeni Yüzyıl ÜniversitesiNot yet recruitingSleep Quality | Heart Rate Variability | Stress LevelTurkey
-
Fatima Jinnah Women UniversityCompletedSuicidal Ideation | Psychological Distress | Non-Suicidal Self InjuryPakistan
-
Alexandria UniversityCompleted
-
İstanbul Yeni Yüzyıl ÜniversitesiNot yet recruitingWell-being | Psychological Resilience
-
Washington University School of MedicineTerminated
-
Fatima Jinnah Women UniversityCompletedPhysical DisabilityPakistan
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Georgia...CompletedDiabetes Mellitus, Type 2 | DiabetesUnited States
-
VA Boston Healthcare SystemRecruitingTBI (Traumatic Brain Injury) | Mild Cognitive Impairment (MCI) | Healthy Elderly | Aging | Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease | Alzheimer's Dementia (AD)United States
-
Duke UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedCardiovascular Diseases | Inflammation | Stress, Psychological | SleepUnited States